Paediatric excipient risk assessment (PERA) tool and application for selecting appropriate excipients for paediatric dosage forms - Part 2.

Age-appropriate Excipients Formulation Inactive ingredients Paediatric Risk assessment

Journal

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
Titre abrégé: Eur J Pharm Biopharm
Pays: Netherlands
ID NLM: 9109778

Informations de publication

Date de publication:
07 Aug 2024
Historique:
received: 14 05 2024
revised: 31 07 2024
accepted: 06 08 2024
medline: 10 8 2024
pubmed: 10 8 2024
entrez: 9 8 2024
Statut: aheadofprint

Résumé

It is necessary to use a scientifically sound process for excipient risk evaluation, selection, and management in order to develop paediatric medicinal products that are both safe and effective. The "Paediatric Excipient Risk Assessment (PERA)" framework, which proposes a comprehensive approach by considering all relevant factors related to patient, dosage form, and excipient attributes, was developed and published as part 1 of this paper series, to enable the rational selection of excipients for paediatric medicinal products. This article is Part 2 of the series and presents the PERA tool that allows easy adoption of the PERA framework. Using a straightforward heat map scoring approach (Red, Yellow, and Green category) for risk evaluation, the PERA tool can be used to compare and choose excipients. The PERA tool will help users identify potential gaps in excipients information that will help with risk-based mitigation planning. Several case studies covering frequently used and novel excipients for oral, as well as the choice of excipient for parenteral products for neonatal administration, serve to illustrate the PERA tool's usefulness.

Identifiants

pubmed: 39122051
pii: S0939-6411(24)00273-X
doi: 10.1016/j.ejpb.2024.114447
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

114447

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Anjali Agrawal (A)

Novo Nordisk Inc., 300 North Beacon Street, Suite 501, Watertown, MA 02472, USA. Electronic address: vagr@novonordisk.com.

Smita Salunke (S)

European Paediatric Formulation Initiative (EUPFI), University College London School of Pharmacy, London WC1N 1AX, UK. Electronic address: s.salunke@ucl.ac.uk.

Alfred Rumondor (A)

Bristol Myers Squibb, One Squibb Drive, New Brunswick, NJ 08901, USA. Electronic address: Alfred.Rumondor@bms.com.

Karen Thompson (K)

Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ 07065, USA. Electronic address: karen_thompson@merck.com.

Grazia Caivano (G)

Chiesi Farmaceutici S.p.A. Largo Francesco Belloli 11/A-43122 Parma, Italy. Electronic address: g.caivano@chiesi.com.

Jennifer Walsh (J)

Jenny Walsh Consulting Ltd., Nottingham, UK. Electronic address: jenny@jennywalshconsulting.com.

Brian Enright (B)

Abbvie Inc. 1 N Waukegan Road, North Chicago, IL, 60064, USA. Electronic address: Brian.Enright@abbvie.com.

Philip Sherratt (P)

Bristol Myers Squibb, 556 Morris Avenue, Summit, NJ 07901, USA. Electronic address: Philip.Sherratt@bms.com.

Kevin Hughes (K)

IPEC Europe (International Pharmaceutical Excipients Council) and Colorcon Ltd, Dartford, UK. Electronic address: KHughes@colorcon.com.

David Clapham (D)

Independent Pharmaceutical Consultant, Bishops Stortford, UK. Electronic address: david.clapham@ntlworld.com.

Peter Kuehl (P)

F. Hoffmann La Roche AG, Grenzacher Str. 124, CH-4070 Basel, Switzerland. Electronic address: peter.kuehl@roche.com.

Classifications MeSH